688136 科兴制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)7.4659.1891.931-11.081-4.856
总资产报酬率 ROA (%)3.6974.6471.017-6.143-3.013
投入资产回报率 ROIC (%)4.0745.1411.115-6.734-3.341

边际利润分析
销售毛利率 (%)54.09663.36668.68970.79175.365
营业利润率 (%)24.14410.9594.492-20.351-10.530
息税前利润/营业总收入 (%)29.43613.1816.948-18.179-9.434
净利润/营业总收入 (%)21.8209.9571.923-15.527-7.054

收益指标分析
经营活动净收益/利润总额(%)-67.92632.915109.898104.758100.529
价值变动净收益/利润总额(%)168.50365.849-34.906-2.6022.282
营业外收支净额/利润总额(%)0.325-1.455-11.0681.4760.363

偿债能力分析
流动比率 (X)1.3451.5741.4531.6922.617
速动比率 (X)1.2231.4381.2931.4062.231
资产负债率 (%)50.49050.40448.16246.19842.938
带息债务/全部投入资本 (%)43.57543.92242.19740.12135.786
股东权益/带息债务 (%)124.207125.376134.890146.148175.534
股东权益/负债合计 (%)98.05598.312107.349116.120133.080
利息保障倍数 (X)5.6475.5402.393-7.340-8.318

营运能力分析
应收账款周转天数 (天)168.654123.79995.92887.48092.144
存货周转天数 (天)88.93790.012136.135195.562211.192